期刊文献+

改良Bethesda方法、改良Nijmegen方法和空白法检测凝血因子Ⅷ抑制物及其影响因素 被引量:2

Modified Bethesda, modified Nijmegen and blank assays for coagulation factor Ⅷ inhibitor detection and factors affecting the results
下载PDF
导出
摘要 目的评价改良Bethesda方法、改良Nijmegen方法和空白法检测血友病A患者凝血因子Ⅷ抑制物的临床应用价值,并探讨凝血因子Ⅷ抑制物检测的影响因素。方法采用改良Bethesda方法、改良Nijmegen方法和以去离子水替代缓冲液或乏Ⅷ因子血浆的空白法,分别检测257例血友病A患者的抑制物水平,以抑制物滴度≥0.60 BU/m L判为阳性结果,并对3种方法检测结果的阳性率及抑制物滴度水平进行分析。结果改良Bethesda方法、改良Nijmegen方法和空白法的阳性率分别为79.38%、85.21%和72.37%。改良Bethesda方法与改良Nijmegen方法之间相关系数为0.996(P<0.001),两种方法的抑制物滴度水平之间有显著的统计学差异(P<0.001),阳性率无显著的统计学差异(P=0.105);改良Bethesda方法与空白法之间相关系数为0.994(P<0.001),抑制物滴度水平之间有显著的统计学差异(P<0.001),阳性率无显著的统计学差异(P=0.079);改良Nijmegen方法与空白法之间相关系数为0.994(P<0.001),抑制物滴度水平之间有显著的统计学差异(P<0.001),阳性率有显著的统计学差异(P=0.001)。结论改良Nijmegen方法具有较高的灵敏度,改良Bethesda方法次之,空白法最差。反应体系中各凝血因子活性水平的一致性是影响凝血因子Ⅷ抑制物检测的主要因素,而稳定的缓冲体系也是影响检测结果稳定性、灵敏度及特异性不可忽视的因素。 Objective To evaluate the dinical value of modified Bethesda assay, modified Nijmegen assay and blank assay for detection of coagulation factor Ⅷ (FⅧ) inhibitors in patients with hemophilia A and analyze the factors that affect FⅧinhibitor detection. Methods The levels of FⅧ inhibitors in 257 patients with hemophilia A were detected using modified Bethesda assay modified Nijmegen assay and blank assay (in which the buffer or FⅧ-deficient plasma in the control mixture was replaced by deionized water). The 3 methods were compared for positivity rates and FⅧ inhibitor titers based on the positive cut-off value of FⅧ inhibitors ≥0.60 BU/mL. Results The positive rates of modified Bethesda assay modified Nijmegen assay and blank assay were 79.38%, 85.21% and 72.37%, respectively. A strong correlation was found between the results by modified Bethesda assay and modified Nijrnegen assay (r=0.996, P〈0.001), and FVIII inhibitor titers (P〈0.001) but not the positive rates (P=0.105) detected by the two methods differed significantly. The correlation coefficients between modified Nijmegen assay and blank assay was 0.994 (P〈0.O01), and a significant difference was found in FVIII inhibitor titers (P〈0.001) but not the positivity rates (P=0.079) detected by the two methods. The correlation coefficient between modified Nijmegen assay and blank assay was 0.994 (r=0.994), and the two methods yielded significantly different FVIII inhibitor titers and positivity rates (P=0.001). Conclusion The modified Bethesda assay has a lower sensitivity than modified Nijmegen assay but has a higher sensitivity than blank assay. The consistency level of coagulation factors in the reaction system and stable buffer system are important factors that affect FⅧ-inhibitor detection.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2016年第4期592-594,F0003,共4页 Journal of Southern Medical University
基金 南方医科大学南方医院新业务新技术课题资助项目(2013019) 南方医科大学大学生创新项目(201512121254)
关键词 改良Bethesda方法 改良Nijmegen方法 空白法 FⅧ抑制物 血友病A modified Bethesda assay modified Nijmegen assay blank assay FⅧ inhibitors hemophilia A
  • 相关文献

参考文献18

  • 1Bolton-Maggs PH, Pasi KJ. Haemophilias a and B[J]. Lancet, 2003, 361(9371): 1801-9.
  • 2Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors Ⅷ and Ⅸ[J]. HaemoPhilia, 2006, 12: 15-22.
  • 3Martin PG, Sukhu K, Chambers E, et al. Evaluation of a novel ELISA screening test for detection of factor Ⅷ inhibitory antibodies in haemophiliacs[J]. Clin Lab Haematol, 1999, 21(2): 125-8.
  • 4Kreuz W, Becker S, Lenz E, et al. Factor Ⅷ inhibitors in Patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor Ⅷ [J]. Semin Thromb Hemost, 1995, 21: 382-9.
  • 5Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor Ⅷ concentrates[J]. J Thromb Haemost, 2006, 4(12): 2576-81.
  • 6Martin PG, Sukhu K, Chambers E, et al. Evaluation of a novel ELISA sereening test for detection of factor Ⅷ in hibitory antibodies in haemoPhiliaes [J]. Clin Lab Haematol, 1999, 21: 125-8.
  • 7Saenko EL, Ananyeva NM, Kouiavskaia DV, et al. Haemophilia a: effects of inhibitory antibodies on factor Ⅷ functional interactions and approaches to prevent their action[J]. Haemophilia, 2002, 8(1): 1-11.
  • 8张露璐,余自强,张威,曹丽娟,苏健,白霞,阮长耿.TNF-α及CTLA-4基因多态性与中国汉族血友病A患者血浆凝血因子Ⅷ抑制物发生的相关性研究[J].中华血液学杂志,2011,32(3):168-172. 被引量:4
  • 9Gouw SC~ Van Den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis [J]. Blood, 2012, 119(12): 2922-34.
  • 10Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review[J]. Haemophilia, 2003, 9(4): 418-35.

二级参考文献48

  • 1Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates [ J]. J Thromb Haemost, 2006, 4(12) :2576-2581.
  • 2Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX [J]. Haemophilia, 2006, 12(Suppl 6) : 15-22.
  • 3Sharifian R, Hoseini M, Safai R, et al. Prevalence of inhibitors in a population of 1 280 hemophilia a patients in Iran [J]. Acta Medica Iranica, 2003, 41 ( 1 ) :66-68.
  • 4Arun B, Kessler CM. Clinical manifestations and therapy of the hemophilias [ M ] //Coleman RW, Hirsh J, Mader VJ, et al. Hemostasis and thrombosis: basic principles and clinical practice inherited hemorrhagic disorders. 4th ed. Philadephia: J P Linppicott Williams and Wilkins, 2001: 815 -824.
  • 5Lusher M, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A [ J ]. Haemophilia, 2003, 9(1) :34-49.
  • 6Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A [J]. Blood, 2006, 107(1) :46-51.
  • 7Santagostino E, Mancuso ME, Rocino A, et al. Environ- mental risk factors for inhibitor development in children with haemophilia A: a case-control study [ J ]. Br J Haematol, 2005, 130 (3) :422 -427.
  • 8Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A [J]. Haemophilia, 2007, 13 (2) :149-155.
  • 9DiMichele DM. Inhibitors in hemophilia: a primer [ J ]. Haemophilia, 2000, 6 ( Suppl 1 ) :38-40.
  • 10d'Orion R, Lavergne JM, Goudemand J, et al. Mild/moderate hemophilia A with factor VIII inhibitors (MHAI) : results of a French and Belgian survey [J]. Blood, 2004, 104 (abstract) :3088.

共引文献20

同被引文献13

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部